Yesterday during Regeneron Pharmaceutical’s Q2 earnings call, Regeneron announced that its Antibody Discovery Agreement with Sanofi will be ending on December 31, 2017 without an extension.
Regeneron’s President and Chief Scientific Officer, George D. Yancopoulos, stated that Regeneron and Sanofi will continue their collaboration with respect to drugs discovered and initially developed under the Antibody Discovery Agreement, including Praluent (alirocumab) and Dupixent (dupilumab), both of which are the subject of ongoing litigation (see our previous coverage here and here).
With respect to the Praluent litigation (Amgen v. Sanofi/Regeneron), Regeneron’s President and Chief Executive Officer, Leonard S. Schleifer, stated on the earnings call that the company is currently awaiting a Federal Circuit opinion following the oral arguments held in early June.